Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. It is in contrast to a “one-size-fits-all” approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration of the differences between individuals.
Researchers at WID with expertise in complex biological systems, epigenetics, data science, health care, gene editing, and tissue engineering will contribute to “healthy people” initiatives through precison medicine.
Precision medicine is an important component of WID’s Multi-Omics Hub.
WID’s Sarah Gong is part of a team that developed a micro-molded scaffolding photoreceptor “patch” to be implanted under damaged or diseased retinas, the next step in restoring sight.
Shaoqin “Sarah” Gong collaborates on a new approach to target genetic mutations and develop a new therapy for restoring vision in children and adults.
Using an ingenious microscopic retinal patch, eye researchers at UW‒Madison will develop and test a new way to treat United States military personnel blinded in combat. WID’s Sarah Gong is a collaborator on the project.
WID’s Randolph Ashton, Gavin Knight, Benjamin Knudsen, and Nisha Iyer take top honors from the Wisconsin Alumni Research Foundation’s Innovation Awards. Their work, Superior Neural Tissue Models for Disease Modeling, Drug Development and More, was selected from more than 400 innovation disclosures.
By combing the ocean for antimicrobials, scientists at the University of Wisconsin–Madison have discovered a new antifungal compound that efficiently targets multi-drug-resistant strains of deadly fungi without toxic side effects in mice. WID postdoc Marc Chevrette is part of the team that published the finding in Science.
WID’s Kris Saha was among UW–Madison researchers who have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.
A team of UW-Madison researchers led by Discovery Fellow Wendy Crone has created a powerful tool to help assess what experimental factors help to produce stem cell-generated cardiomyocytes that behave like adult heart cells.
WID’s Kris Saha spoke to Wisconsin Public Radio to answer questions about gene editing technology CRISPR in response to a question received by WHYsconsin.
WID researchers have developed a computational tool that can accurately predict the three-dimensional interactions between regions of human chromosomes.
An interdisciplinary pair of WID researchers has developed a new nanocapsule delivery method for delivering the CRISPR-Cas9 gene editing tool. The new system could be used for many types of gene therapies.
Researchers at the Wisconsin Institute for Discovery are co-Principal Investigators and co-Investigators on four UW2020: WARF Discovery Initiative projects.
WID researchers used a collaborative combination of computational and wet lab experimental techniques to find a connection between a transcription factor and a neurodevelopment gene.
WID’s Tom Turng envisions a future in which surgeons can order mass-produced artificial blood vessels that arrive ready to use in bypass surgeries.
WID’s new hubs—Data Science, Multi-Omics, and Illuminating Discovery—represent a new path forward for collaborative research projects and fields.
A paper published in eLife this week by an interdisciplinary team at WID describes new methods for reproducibly manufacturing brain and spinal cord organoids with strict control over morphogenic and developmental processes.
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
One of the UW Carbone Cancer Center members presenting is WID’s Peter Lewis. His work focuses on how genes are turned on and off during embryonic development, and how misregulation in those genes can lead to some childhood cancers.
WID researcher Shaoqin Sarah Gong is working to more safely deliver a variety of drugs to treat cancer, heart disease and even blindness.
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
Xuehua Zhong recently received an outstanding investigator award from NIH via the Maximizing Investigators’ Research Award (MIRA) mechanism to support her research. She talked about how she uses plants to study epigenetics in an interview with Grow magazine.
Wisconsin Institute for Discovery (WID) researchers Rupa Sridharan and Sushmita Roy are combining their expertise in regenerative biology and computational biology to better understand how cells transition from one type to another through gene regulation.
Machine learning is a form of artificial intelligence by which algorithms are “trained” to analyze new information using existing data. Researchers are using it to identify individuals with a genetic condition known as fragile X premutation.
WID researchers Stephen Wright and Robert Nowak are part of a UW2020: WARF Discovery Initiative project to create machine learning tools that dramatically reduce the time and cost associated with screening compounds for therapeutic relevance.
The Living Environments Laboratory will host the Ethics in Investigational & Interventional Uses of Virtual Reality (e3iVR) conference beginning with public talks on the afternoon of April 26. More information and registration are at go.wisc.edu/e3iVR.
